Strengthening acquisition, research efforts will support warfighter readiness and military healthcare services
Published . Updated .
Key takeaways
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report is about defense and pharma and health.
Directly affected
- No company is named in this report.
Indirectly affected
- ITA iShares U.S. Aerospace & Defense ETF+0.3% 30d
iShares U.S. Aerospace & Defense ETF: it holds defense and aerospace contractors. Linked by “military” (defense) in this story.
- XAR SPDR S&P Aerospace & Defense ETF-4.4% 30d
SPDR S&P Aerospace & Defense ETF: it holds defense and aerospace contractors. Linked by “military” (defense) in this story.
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story.
- LLY Eli Lilly and+20.6% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
- JNJ Johnson & Johnson+0.5% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
- PFE Pfizer+9.0% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
- MRK Merck+4.6% 17d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| ITA | -3.96% | -0.11% | base | +0.81% | after close | after close | after close |
| XAR | -2.82% | +1.94% | base | +1.37% | after close | after close | after close |
| XLV | -2.95% | -0.31% | base | -0.22% | after close | after close | after close |
| LLY | -9.22% | -2.71% | base | -0.36% | after close | after close | after close |
| JNJ | -0.68% | +1.70% | base | -1.89% | after close | after close | after close |
| PFE | -3.00% | -2.47% | base | -2.57% | after close | after close | after close |
| MRK | -4.45% | -1.43% | base | -3.28% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Strengthening acquisition, research efforts will support warfighter readiness and military healthcare services DVIDS
Source: DVIDS
The price since 3 Nov 2026: IShares U.S. Aerospace & Defense ETF (ITA) versus the S&P 500
| Company | When | Move | Status |
|---|---|---|---|
| IShares U.S. Aerospace & Defense ETF (ITA) | that day | +0.81% | final price |
| IShares U.S. Aerospace & Defense ETF (ITA) | three days earlier | -0.11% | final price |
| IShares U.S. Aerospace & Defense ETF (ITA) | five days earlier | -3.96% | final price |
| Johnson & Johnson (JNJ) | that day | -1.89% | final price |
| Johnson & Johnson (JNJ) | three days earlier | +1.70% | final price |
| Johnson & Johnson (JNJ) | five days earlier | -0.68% | final price |
| Eli Lilly (LLY) | that day | -0.36% | final price |
| Eli Lilly (LLY) | three days earlier | -2.71% | final price |
| Eli Lilly (LLY) | five days earlier | -9.22% | final price |
| Merck (MRK) | that day | -3.28% | final price |
| Merck (MRK) | three days earlier | -1.43% | final price |
| Merck (MRK) | five days earlier | -4.45% | final price |
| Pfizer (PFE) | that day | -2.57% | final price |
| Pfizer (PFE) | three days earlier | -2.47% | final price |
| Pfizer (PFE) | five days earlier | -3.00% | final price |
| Spdr Series Trust (XAR) | that day | +1.37% | final price |
| Spdr Series Trust (XAR) | three days earlier | +1.94% | final price |
| Spdr Series Trust (XAR) | five days earlier | -2.82% | final price |
| Select Sector Spdr Tr (XLV) | that day | -0.22% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | -0.31% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -2.95% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 34 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 56 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 74 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 76 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
IShares U.S. Aerospace & Defense ETF (ITA) on one side of this defense story
Companies tied to this story
- ITA IShares U.S. Aerospace & Defense ETF
IShares U.S. Aerospace & Defense ETF (ITA) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “Strengthening acquisition, research efforts will support warfighter readiness and military healthcare services.” Reason on file: iShares U.S. Aerospace & Defense ETF: it holds defense and aerospace contractors. Linked by “military” (defense) in this story
- XAR Spdr Series Trust
Spdr Series Trust (XAR) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “Strengthening acquisition, research efforts will support warfighter readiness and military healthcare services.” Reason on file: SPDR S&P Aerospace & Defense ETF: it holds defense and aerospace contractors. Linked by “military” (defense) in this story
- XLV Select Sector Spdr Tr
For “Strengthening acquisition, research efforts will support warfighter readiness and military healthcare services,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “healthcare” (pharma and health) in this story
- LLY Eli Lilly
For “Strengthening acquisition, research efforts will support warfighter readiness and military healthcare services,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story
- JNJ Johnson & Johnson
For “Strengthening acquisition, research efforts will support warfighter readiness and military healthcare services,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story
- PFE Pfizer
Pfizer (PFE) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “Strengthening acquisition, research efforts will support warfighter readiness and military healthcare services.” Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story
- MRK Merck
For “Strengthening acquisition, research efforts will support warfighter readiness and military healthcare services,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “healthcare” (pharma and health) in this story
IShares U.S. Aerospace & Defense ETF (ITA) and the defense link
IShares U.S. Aerospace & Defense ETF (ITA) is the company in “Strengthening acquisition, research efforts will support warfighter readiness and military healthcare services,” the 3 Nov 2026 Defense story.
The link for IShares U.S. Aerospace & Defense ETF (ITA) is this: iShares U.S. Aerospace & Defense ETF: it holds defense and aerospace contractors. Linked by “military” (defense) in this story
A second company, Spdr Series Trust (XAR), is listed for a different reason: SPDR S&P Aerospace & Defense ETF: it holds defense and aerospace contractors. Linked by “military” (defense) in this story
What this defense story puts on the calendar
ITA traded between 197.59 and 215.76 across 20 sessions. The latest close on file is 214.70. XAR traded between 210.89 and 237.55 across 20 sessions. The latest close on file is 231.04.
How strong the case is around IShares U.S. Aerospace & Defense ETF (ITA)
46 out of 100
“Strengthening acquisition, research efforts will support warfighter readiness and military healthcare services” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.